Results for this period
Interim period (second quarter)1 April 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Increased sales of closed systems for drug compounding and administration, infusion pumps, component blood collection circuits, blood bags and other products lifted revenue and operating profit, while lower sales of hemodialysis equipment for China and AVF needles for North America, higher raw material and other costs and personnel expenses, and foreign exchange losses weighed on profit.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥32,391 million (YoY +0.5%) |
| Operating profit | ¥9 million |
| Ordinary income | ¥-145 million |
| Profit attributable to owners of the parent | ¥-262 million |
| Net income per share | -¥10.69 |
| Equity ratio | End of the current fiscal period 50.5 / End of previous period 50.2 |
| Total assets | ¥82,922 million |
| Net assets | ¥41,916 million |
| Cash flows from operating activities | ¥2,140 million |
| Cash flows from investing activities | ¥-965 million |
| Cash flows from financing activities | ¥-1,384 million |
| Cash and cash equivalents at end of period | ¥7,482 million |
| Full-year earnings forecast | Net Sales ¥68,000 million (YoY +3.3%) / Operating profit ¥700 million (YoY +83.5%) / Ordinary income ¥400 million (YoY +12.2%) / Profit attributable to owners of the parent ¥100 million |
| Annual Dividend Forecast | ¥17 → ¥17（0.0%） |
| Segment revenue | Segment Japan / Net Sales ¥21,715 million / Year-on-year (%) -1, Segment Singapore / Net Sales ¥12,443 million / Year-on-year (%) 5.9, Segment China / Net Sales ¥2,160 million / Year-on-year (%) 4.6, Segment Philippines / Net Sales ¥1,925 million / Year-on-year (%) 16.8, Segment Germany / Net Sales ¥1,857 million / Year-on-year (%) -11, Segment Other / Net Sales ¥2,333 million / Year-on-year (%) -19.9 |
| Segment profit | Segment Japan / Segment profit ¥297 million / Year-on-year (%) -1.2, Segment Singapore / Segment profit ¥-222 million / Year on year against the same period last year Not disclosed, Segment China / Segment profit ¥121 million / Year-on-year (%) 40.7, Segment Philippines / Segment profit ¥-332 million / Year on year against the same period last year Not disclosed, Segment Germany / Segment profit ¥201 million / Year-on-year (%) -20.6, Segment Other / Segment profit ¥6 million / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | ¥1,934 million |
| Breakdown of extraordinary income (loss) | Category Extraordinary income / Item Gain on sale of fixed assets / Amount ¥10 million, Category Extraordinary Losses / Item Loss on sale of non-current assets / Amount ¥2 million, Category Extraordinary Losses / Item Loss on disposal of fixed assets / Amount ¥6 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Available / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Available (participants not specified) |
| Issued Shares at Period-End | 24,733,466 shares |
| Treasury Shares at Period-End | 182,479 treasury shares |
| Factors Behind Changes in Business Performance | Increased sales of closed systems for drug compounding and administration, infusion pumps, component blood collection circuits, blood bags and other products lifted revenue and operating profit, while lower sales of hemodialysis equipment for China and AVF needles for North America, higher raw material and other costs and personnel expenses, and foreign exchange losses weighed on profit. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, sales increased for closed systems for drug compounding and administration and infusion pumps, while overseas sales increased for component blood collection circuits and blood bags. Sales of hemodialysis equipment for China and AVF needles for North America declined. Operating profit improved due to the earnings contribution from higher sales of core products, but increases in raw material and other costs, personnel expenses, and foreign exchange losses weighed on profit. In addition, depreciation increased by ¥18 million because the estimated remaining useful life of the former office building was shortened. The detailed reasons for the revision to the earnings forecast are not provided in this earnings report, which refers readers to a separate disclosure document.